Patients treated with intravitreal triamcinolone acetonide [from Gallenga and Lobefalo] and Response to correspondence [from Kocabora]  ||FREE PAPER||

Pier E Gallenga1, Lucio Lobefalo21University Eye Clinic, G.D’Annunzio University, Chieti, Italy; 2Ethical Committee, Italian Ophthalmological Society – SOI, ItalyThe paper by Kocabora and coworkers (2008) underlines the message that patients treated with intravitreal tria...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Pier E Gallenga, Lucio Lobefalo, M Selim Kocabora
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2008
Materias:
Acceso en línea:https://doaj.org/article/cd005902712d4e0daab2add1786f68cf
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:cd005902712d4e0daab2add1786f68cf
record_format dspace
spelling oai:doaj.org-article:cd005902712d4e0daab2add1786f68cf2021-12-02T03:04:38ZPatients treated with intravitreal triamcinolone acetonide [from Gallenga and Lobefalo] and Response to correspondence [from Kocabora]  ||FREE PAPER||1177-54671177-5483https://doaj.org/article/cd005902712d4e0daab2add1786f68cf2008-06-01T00:00:00Zhttp://www.dovepress.com/patients-treated-with-intravitreal-triamcinolone-acetonide-from-gallen-a1807https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Pier E Gallenga1, Lucio Lobefalo21University Eye Clinic, G.D’Annunzio University, Chieti, Italy; 2Ethical Committee, Italian Ophthalmological Society – SOI, ItalyThe paper by Kocabora and coworkers (2008) underlines the message that patients treated with intravitreal triamcinolone acetonide are at risk of increased intraocular pressure (IOP) even after the clearance period of the drug. Furthermore, the development of intractable secondary glaucoma requiring surgical intervention is clear advice to monitor these patients carefully. M Selim KocaboraVatan caddesi, Vakif Gureba Egitim ve Arastirma Hastanesi, Fatih, 34 000, Istanbul, Turkey.We thank Dr. Gallenga and Dr. Lobefalo for their interest in our article (Kocabora et al 2008) and for their comments. We agree with them on the importance of pharmacovigilance and of warning the ophthalmology community about the potential risks of intravitreal triamcinolone (IVTA). We should always follow the principle of primum, non nocere in our medical practices. ... Pier E GallengaLucio LobefaloM Selim KocaboraDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2008, Iss Issue 2, Pp 483-484 (2008)
institution DOAJ
collection DOAJ
language EN
topic Ophthalmology
RE1-994
spellingShingle Ophthalmology
RE1-994
Pier E Gallenga
Lucio Lobefalo
M Selim Kocabora
Patients treated with intravitreal triamcinolone acetonide [from Gallenga and Lobefalo] and Response to correspondence [from Kocabora]  ||FREE PAPER||
description Pier E Gallenga1, Lucio Lobefalo21University Eye Clinic, G.D’Annunzio University, Chieti, Italy; 2Ethical Committee, Italian Ophthalmological Society – SOI, ItalyThe paper by Kocabora and coworkers (2008) underlines the message that patients treated with intravitreal triamcinolone acetonide are at risk of increased intraocular pressure (IOP) even after the clearance period of the drug. Furthermore, the development of intractable secondary glaucoma requiring surgical intervention is clear advice to monitor these patients carefully. M Selim KocaboraVatan caddesi, Vakif Gureba Egitim ve Arastirma Hastanesi, Fatih, 34 000, Istanbul, Turkey.We thank Dr. Gallenga and Dr. Lobefalo for their interest in our article (Kocabora et al 2008) and for their comments. We agree with them on the importance of pharmacovigilance and of warning the ophthalmology community about the potential risks of intravitreal triamcinolone (IVTA). We should always follow the principle of primum, non nocere in our medical practices. ...
format article
author Pier E Gallenga
Lucio Lobefalo
M Selim Kocabora
author_facet Pier E Gallenga
Lucio Lobefalo
M Selim Kocabora
author_sort Pier E Gallenga
title Patients treated with intravitreal triamcinolone acetonide [from Gallenga and Lobefalo] and Response to correspondence [from Kocabora]  ||FREE PAPER||
title_short Patients treated with intravitreal triamcinolone acetonide [from Gallenga and Lobefalo] and Response to correspondence [from Kocabora]  ||FREE PAPER||
title_full Patients treated with intravitreal triamcinolone acetonide [from Gallenga and Lobefalo] and Response to correspondence [from Kocabora]  ||FREE PAPER||
title_fullStr Patients treated with intravitreal triamcinolone acetonide [from Gallenga and Lobefalo] and Response to correspondence [from Kocabora]  ||FREE PAPER||
title_full_unstemmed Patients treated with intravitreal triamcinolone acetonide [from Gallenga and Lobefalo] and Response to correspondence [from Kocabora]  ||FREE PAPER||
title_sort patients treated with intravitreal triamcinolone acetonide [from gallenga and lobefalo] and response to correspondence [from kocabora]  ||free paper||
publisher Dove Medical Press
publishDate 2008
url https://doaj.org/article/cd005902712d4e0daab2add1786f68cf
work_keys_str_mv AT pieregallenga patientstreatedwithintravitrealtriamcinoloneacetonidefromgallengaandlobefaloandresponsetocorrespondencefromkocaboraampnbspfreepaper
AT luciolobefalo patientstreatedwithintravitrealtriamcinoloneacetonidefromgallengaandlobefaloandresponsetocorrespondencefromkocaboraampnbspfreepaper
AT mselimkocabora patientstreatedwithintravitrealtriamcinoloneacetonidefromgallengaandlobefaloandresponsetocorrespondencefromkocaboraampnbspfreepaper
_version_ 1718402008611815424